Schedule-Dependent Cytotoxicity of Etoposide and Cyclophosphamide in P-Glycoprotein-Expressing Human Leukemic K-562 Cells

DOI HANDLE Web Site Web Site PubMed 参考文献7件 オープンアクセス
  • Tazawa Yuki
    Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University
  • Usukubo Ippei
    Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University
  • Takada Kazuki
    Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University
  • Takekuma Yoh
    Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University
  • Shibayama Yoshihiro
    Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University
  • Sugawara Mitsuru
    Laboratory of Pharmacokinetics, Faculty of Pharmaceutical Sciences, Hokkaido University Education Research Center for Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Hokkaido University

この論文をさがす

抄録

Combination chemotherapy is often used to treat cancer. Many studies have shown schedule-dependent effects between anticancer drugs. Our previous studies showed that K-562 cells pretreated with non-cytotoxic concentrations of 4-hydroperoxycyclophosphamide (4-HPC), which is a preactivated analog of cyclophosphamide (CY), enhanced the cytotoxicity of etoposide (VP-16). The appearance of cellular resistance to anticancer drugs is a major problem in cancer chemotherapy. P-Glycoprotein (P-gp) plays an important role in drug resistance, and VP-16 is a substrate for this efflux pump. In the present study, we demonstrated schedule-dependent cytotoxicity of VP-16 and CY in P-gp-overexpressed K-562/P-gp cells. Cytotoxicity of VP-16 was enhanced in K-562/P-gp cells that were pretreated with a non-cytotoxic concentration of 4-HPC compared to that of cells not treated with 4-HPC. 4-HPC arrested the cell cycle at S phase. Cells in S phase are most sensitive to VP-16. The results suggest that cell cycle arrest by 4-HPC pretreatment may be responsible for the enhanced cytotoxicity of VP-16. The findings in this study should lead to improvements in clinical combination chemotherapy.

収録刊行物

参考文献 (7)*注記

もっと見る

関連プロジェクト

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ